Introducing SMi's 6th annual conference on Pharmaceutical Freeze Drying Technology this June 2018

SMi Group13 - 14 June 2018, London, UK.
Although an old process, pharmaceutical freeze drying is ever evolving with new trends and approaches being used for pharmaceutical formulation. In it's 6th year, the conference will cover the most recent advances in Freeze drying technology and discuss the latest ideas in the industry. It is the perfect platform to strengthen knowledge in key principles such as PAT and QbD, whilst staying at the forefront of technological breakthroughs to adapt to growing manufacturing demands.

Gathering a room of Senior Scientists and Heads of Pharmaceutical Engineering, the 6th annual show provides an ideal forum to discuss the latest advancements in pharmaceutical lyophilisation, welcoming regulatory guidance from the NIBSC-MHRA and expertise from the likes of Sanofi, Boehringer Ingelheim, Janssen, GSK and more.

Network & Benefit From Industry Experts:

  • [CHAIR] SuneKlint Anderson, Principal Scientist, Janssen
  • Paul Matejtschuk, Principal Scientist, NIBSC - MHRA
  • Mostafa Nakach, Head of Pharmaceutical Engineering, Sanofi
  • ErwanBourles, Expert Scientist, Head Filling Drying Device, GlaxoSmithKline
  • MiguelaVieru, Senior Scientist, Janssen
  • Eric Munson, Patrick Deluca Endowed Professor of Pharmaceutical Technology, University of Kentucky
  • Patrick Garidel, Bioprocess and Pharmaceutical Development Biologicals, Boehringer Ingelheim
  • Daryl Williams, Reader in Particle Science, Imperial College London

Featured Highlights this June:

  • Discuss the use of old and new methods in terms of the optimisation of freeze drying cycles
  • Learn about case studies which delve into the processes through which cycles can be refined to the utmost efficiency
  • Hear about a new PAT for freeze drying cycle development through vial impedance spectroscopy
  • Discover ways in which water activity measurement and mathematical modelling can be used to evaluate the stability of freeze dried vaccines
  • Evaluate quality-by-design strategies, applied to spray drying, versus lyophilisation

Don't forget to check out the two-post conference interactive workshops taking place on 12th June.

For those looking to attend there are early-bird rates currently available of up to £400.

Further information is available at: www.pharmafreezedrying.com/wpn

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

Novartis receives FDA approval for Mayzent® (sipon…

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple scl...

First bacterial genome created entirely with a com…

All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United Sta...

Clinical trial finds therapy to be well-tolerated …

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated...

Liver, colon cancer cells thwarted by compounds de…

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as w...

Compound that kills drug-resistant fungi is isolat…

Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a...

Boehringer Ingelheim announces FDA and EMA regulat…

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and E...

Selumetinib granted US Breakthrough Therapy Design…

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) ha...

FDA approves treatment for patients with a type of…

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called no...

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T...

Novartis adds clinical and preclinical anti-inflam…

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC fo...

Immune cells fighting blood cancer visualized for …

When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) re...

Bayer reaches settlement to resolve Xarelto™ litig…

More than five years after the Xarelto™ litigation began, and with Bayer and Janssen Pharmaceuticals prevailing in all six cases that went to trial, the companies have re...